Celltrion
FDA Approves Herzuma for Breast Cancer
The FDA approved Herzuma, a HER2/neu receptor antagonist biosimilar to Herceptin for breast cancer treatment.
DECEMBER 17, 2018
FDA Approves Truxima, First Biosimilar to Rituxan
Truxima can be used to treat three types of adults with non-Hodgkin lymphoma.
NOVEMBER 29, 2018
FDA Approves Inflectra, Biosimilar to Remicade
Inflectra is the second U.S. biosimilar approved and the first monoclonal antibody.
APRIL 6, 2016
Load more